Toward a Single-Dose Cure for Buruli Ulcer
Sangeeta Susan Thomas, Nitin Pal Kalia, Marie‐Thérèse Ruf, Gerd Pluschke, Kévin Pethe
Abstract
A single dose of Q203 (Telacebec), a phase 2 clinical candidate for tuberculosis, eradicates Mycobacterium ulcerans in a mouse model of Buruli ulcer infection without relapse up to 19 weeks posttreatment. Clinical use of Q203 may dramatically simplify the clinical management of Buruli ulcer, a neglected mycobacterial disease.
Topics & Concepts
Buruli ulcerMycobacterium ulceransMedicineTuberculosisMycobacterium tuberculosisSkin ulcerDermatologyDiseaseInternal medicinePathologyMycobacterium research and diagnosisInfectious Diseases and MycologyTuberculosis Research and Epidemiology